Nitroreductase: A prodrug-activating enzyme for cancer gene therapy

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 11, 2004, Pages 811-816

  Searle, Peter F ^a   Chen, Ming Jen ^a,d   Hu, Longqin ^c   Race, Paul R ^a   Lovering, Andrew L ^a   Grove, Jane I ^a,b   Guise, Chris ^a   Jaberipour, Mansooreh ^a   James, Nicholas D ^a   Mautner, Vivien ^a   Young, Lawrence S ^a   Kerr, David J ^a,e   Mountain, Andrew ^b   White, Scott A ^a   Hyde, Eva I ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c RUTGERS UNIVERSITY   (United States)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Bacteriophage lambda; Cancer; CB1954; Clinical trial; Escherichia coli; Gene therapy; Nitro reductase; Oncolytic viruses; Prodrug; Protein engineering

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 [N,N BIS(2 CHLORETHYL)AMINO] 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; BENZAMIDE DERIVATIVE; NITROREDUCTASE; PRODRUG; SN 23862; UNCLASSIFIED DRUG;

ADENOVIRUS; BACTERIOPHAGE LAMBDA; CANCER GENETICS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA CROSS LINKING; DRUG STRUCTURE; ESCHERICHIA COLI; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; OVARY CARCINOMA; PATIENT SELECTION; PROSTATE CANCER; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC ENGINEERING; HUMANS; NEOPLASMS; NITROREDUCTASES; PRODRUGS;

EID: 9344252858     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04085.x     Document Type: Conference Paper

References (45)

1. Cobb LM, Connors TA, Elson LA et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): A potent and selective inhibitor of growth of the Walker carcinoma 256. Biochem. Pharmacol. 1969; 18: 1519-27.
2. Roberts JJ, Friedlos F, Knox RJ. CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 1986; 140: 1073-8.
3. Knox RJ, Friedlos F, Jarman M, Roberts JJ. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 1988; 37: 4661-9.
4. Knox RJ, Boland M, Friedlos F, Coles B, Southan C, Roberts JJ. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 1988; 37: 4671-7.
5. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol. 1991; 41: 867-75.
6. Chen S, Knox R, Wu K et al. Molecular basis of the catalytic differences among DT-diaphorase of human, rat and mouse. J. Biol. Chem. 1997; 272: 1437-9.
7. Venitt S, Crofton-Sleigh C. The toxicity and mutagenicity of the anti-tumour drug 5-aziridino-2,4-dinitrobenzamide (CB 1954) is greatly reduced in a nitroreductase-deficient strain of E. coli. Mutagenesis 1987; 2: 375-81.
8. McCalla DR, Kaiser C, Green MH. Genetics of nitrofurazone resistance in Escherichia coli. J. Bacteriol. 1978; 133: 10-16.
9. Sastry SS, Jayaraman R. Nitrofurantoin-resistant mutants of Escherichia coli: Isolation and mapping. Mol. Gen. Genet. 1984; 196: 379-80.
10. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954): I. Purification and properties of a nitroreductase enzyme from Escherichia coli: A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992; 44: 2289-95.
11. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 1992; 44: 2297-301.
12. Michael NP, Brehm JK, Anlezark GM, Minton NP. Physical characterization of the Escherichia coli B gene encoding nitro-reductase and its overexpression in Escherichia coli K12. FEMS Microbiol. Lett. 1994; 124: 195-202.
13. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 1995; 31A: 2362-70.
14. Green NK, Youngs DJ, Neoptolemos JP et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 1997; 4: 229-38.
15. McNeish IA, Green NK, Gilligan MG et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998; 5: 1061-9.
16. Weedon SJ, Green NK, McNeish IA et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 2000; 86: 848-54.
17. Djeha AH, Hulme A, Dexter MT et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 2000; 7: 721-31.
18. Djeha AH, Thomson TA, Leung H et al. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol. Ther. 2001; 3: 233-40.
19. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 1997; 8: 709-17.
20. Green NK, Youngs DJ, Young LS, Kerr DJ, Neoptolemos JP, Searle PF. Gene therapy for pancreatic cancer: In vivo killing of tumour cells expressing E. coli nitroreductase following administration of the prodrug CB1954. Gut 1997; 41: A188 (Abstract).
21. Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. Int. J. Cancer 2003; 104: 104-12.
22. Chung-Faye G, Palmer D, Anderson D et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase 1 and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001; 7: 2662-8.
23. Palmer DH, Mautner V, Mirza D et al. Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 2004; 22: 1546-52.
24. Sausville EA. Genes in the service of therapeutic index: Progress for virus-directed enzyme prodrug therapy. J. Clin. Oncol. 2004; 22: 1535-7.
25. James ND, Patel P, Mautner V et al. A clinical trial of virus directed enzyme prodrug therapy (VDEPT) using adenovirus encoded nitro-reductase (ntr) and CB1954 in patients with localized prostate cancer (PCa). Proceedings of the American Society of Clinical Oncology, 5-8 June 2004, New Orleans. American Society of Clinical Oncology, Alexandria. 2004; Abstract 4572.
26. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider. Cancer Gene Ther. 2002; 9: 1062-7.
27. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-21.
28. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997; 3: 639-45.
29. Ries SJ, Brandts CH, Chung AS et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat. Med. 2000; 6: 1128-33.
30. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000; 6: 879-85.
31. Kirn D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 2001; 8: 89-98.
32. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kirn JH. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 1998; 9: 1323-33.
33. Wildner O, Blaese RM, Candotti F. Enzyme prodrug gene therapy. Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 1999; 59: 5233-8.
34. Chen MJ, Green NK, Reynolds GM et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 2004; 11: 1126-36.
35. Anlezark GM, Melton RG, Sherwood RF et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 1995; 50: 609-18.
36. Friedlos F, Denny WA, Palmer BD, Springer CJ. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. 1997; 40: 1270-5.
37. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002; 62: 1425-32.
38. Hu L, Yu C, Jiang Y et al. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J. Med. Chem. 2003; 46: 4818-21.
39. Parkinson GN, Skelly JV, Neidle S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B. A prodrug-activating enzyme. J. Med. Chem. 2000; 43: 3624-31.
40. Lovering AL, Hyde EI, Searle PF, White SA. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: Three crystal forms at 1.7 Å, 1.8 Å and 2.4 Å resolution. J. Mol. Biol. 2001; 309: 203-13.
41. Johansson E, Parkinson GN, Denny WA, Neidle S. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J. Med. Chem. 2003; 46: 4009-20.
42. Grove JI, Lovering AL, Guise C et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res. 2003; 63: 5532-7.
43. Race PR. Studies of the Escherichia coli nitroreductase and selected mutants. PhD thesis, University of Birmingham, UK. 2003.
44. Stemmer WPC. Rapid evolution of a protein in vitro by DNA shuffling. Nature 1994; 370: 389-91.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55-63.